Hedera Dx raises €14 million in seed funding to accelerate global adoption of liquid biopsies
Liquid biopsy cancer testing is one of the most transformational innovations in healthcare for the next decade, directly unlocking better outcomes for patients.Swiss techbio company Hedera Dx , founded in 2021 by veteran healthcare entrepreneurs and executives, will be launching this fall a blood-based testing solution to profile cancer DNA circulating in the blood, helping patients access better treatments. To do this, the company has raised €14M in funding. The round was led by Adam Ghobarah, founder of